Table 1.

Clinical patient characteristics and their association with survival outcomes

				PFS		OS
Characteristics		n	%	HR	P	HR	P
Age (years)	≤60	56	81
	>60	13	19	2.164	0.039	2.489	0.024
Sex	Male	46	33
	Female	23	67	1.215	0.575	0.752	0.494
Performance status	ECOG 0/1	56	81
	ECOG ≥2	13	19	4.372	<0.001	3.736	0.001
Ann Arbor stage	I/II	29/11	42/16
	III/IV	5/24	7/35	1.935	<0.001	1.898	<0.001
Serum LD	Normal	30	44
	Increased	39	56	3.124	0.002	2.456	0.026
B symptoms	Absence	39	56
	Presence	30	44	2.634	0.004	2.310	0.027
LN involvement	Absence	40	58
	Presence	29	42	2.236	0.017	3.258	0.002
Primary site	Nasal	41	59
	Extranasal	28	41	4.092	<0.001	4.240	<0.001
Bone marrow invasion	No	56	81
	Yes	13	19	6.591	<0.001	5.298	<0.001
Extranodal involvement	0/1	43	62
	≥2	26	38	2.948	0.001	2.616	0.011
EBV DNA	Non-detectable	42	61
	Detectable	27	39	4.111	<0.001	3.482	<0.001
IPI	Low/low-intermediate	33/11	48/16
	High-intermediate/High	17/8	24/12	2.482	<0.001	2.031	<0.001
NKPI	Group I/II	18/8	26/12
	Group III/IV	20/23	29/33	2.162	<0.001	2.036	0.001
GPS	0	32	46
	1	22	32
	2	15	22	2.660	<0.001	3.052	<0.001

Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, ECOG Eastern Cooperative Oncology Group, LD lactate dehydrogenase, LN lymph node, EBV Epstein-Barr virus, IPI International Prognostic Index, NKPI NK/T-cell Lymphoma Prognostic Index, CRP C-reactive protein, GPS Glasgow Prognostic Score.